Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned an average rating of “Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $45.13.

DNTH has been the subject of a number of analyst reports. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating for the company. Finally, Oppenheimer began coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 target price for the company.

Dianthus Therapeutics Stock Down 2.9 %

Shares of NASDAQ DNTH opened at $27.50 on Friday. The stock has a market capitalization of $807.68 million, a price-to-earnings ratio of -4.96 and a beta of 1.85. The firm has a 50-day moving average price of $27.77 and a 200 day moving average price of $26.15. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. Equities research analysts expect that Dianthus Therapeutics will post -2.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its position in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $236,000. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Dianthus Therapeutics by 281.9% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after purchasing an additional 29,159 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $334,000. Finally, Great Point Partners LLC raised its holdings in Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after acquiring an additional 132,929 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.